Delivery Order SPE2DB22D1202-SPE2DB25FVLD1
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injectors on August 5, 2025, with completion expected by August 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $2,558.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injectors. This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999.99 billion ceiling value through December 2026. The delivery order is non-set-aside and was competitively awarded. Performance will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector medication valued at $1,127.92. This is a firm fixed price delivery order with an ultimate completion date of August 12, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under...
- The Defense Logistics Agency awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of September 15, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the vendor performing the work at its corporate office location in the same municipality. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a $1,629.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector pharmaceutical supplies, with an ultimate completion date of July 21, 2025. This non-set-aside competitively awarded contract represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a $1,270.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The delivery...
- The Defense Logistics Agency (DLA) awarded a $2,935.72 delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injectors on September 4, 2025, with a completion date of September 5, 2025. This competitively awarded, firm fixed-price order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,086.44 to AmerisourceBergen Drug Corp for the supply of Xyosted 75 mg/0.5 ml auto-injector units. The contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will occur at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency has awarded a $1,233.05 delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supply, with an ultimate completion date of September 4, 2025. This firm fixed price contract, awarded on September 3, 2025, represents a non-set-aside competitive award for pharmaceutical products to be delivered to the Conshohocken, Pennsylvania facility. The delivery order falls under AmerisourceBergen's broader indefinite delivery contract with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,086.44 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector pharmaceutical product on September 12, 2025, with an ultimate completion date of September 15, 2025. This is a firm fixed price delivery order with no set-aside designation, executed through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVLD1Delivery Order
The Defense Logistics Agency (DLA) awarded a $10,032.76 delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector supplies on September 12, 2025, with completion targeted for September 15, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement that extends through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical federal vendor for military and veteran healthcare systems through its comprehensive medical supply chain capabilities. The company's IDC vehicle enables supply of a broad range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for testosterone replacement therapy demonstrates the company's role in fulfilling specialized pharmaceutical needs within the federal medical procurement system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.0k | 9/12/25 |